Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 3/2017

01-03-2017 | Review

Usage of the levonorgestrel-releasing intrauterine system (LNG-IUS) in adolescence: what is the evidence so far?

Authors: Magdalini Patseadou, Lina Michala

Published in: Archives of Gynecology and Obstetrics | Issue 3/2017

Login to get access

Abstract

Purpose

The levonorgestrel-releasing intrauterine system (LNG-IUS) is an effective method of contraception, while also providing various non-contraceptive benefits. Although targeted primarily to adults, there is increasing experience in its use in adolescence. The aim of this review is to assess the available information on LNG-IUS usage in adolescence.

Methods

We conducted an online search on MEDLINE and SCOPUS from inception to May 24, 2015. All studies that examined LNG-IUS use in teen populations were eligible for inclusion. Primary outcome measures included description of indications for LNG-IUS usage and relevant efficacy. Secondary outcomes included complications, such as device-related problems (perforation and expulsion) and other adverse events (pelvic inflammatory disease, PID). Acceptability of the LNG-IUS was also estimated through evaluation of continuation rate and reasons for removal were assessed.

Results

Twenty-one studies met our inclusion criteria. We identified only one randomized controlled trial (RCT). All other twenty studies were observational. Pregnancy rates ranged from 0 to 2.7%. Management of heavy or/and painful periods was successful in 92–100%. Menstrual manipulation in patients with developmental delay was achieved in over 93% of cases. Expulsion rates ranged from 0 to 13% and pelvic infection/cervicitis between 0 and 2.7%. There were no reported uterine perforations.

Conclusion

Usage of the LNG-IUS in teen populations appears to be safe and efficacious both in terms of contraception and menstrual management. However, more robust evidence is needed so as to provide firm confirmation on benefits and potential side effects.
Literature
1.
2.
Jonsson B, Landgren B-M, Eneroth P (1991) Effects of various IUDs on the composition of cervical mucus. Contraception 43:447–458CrossRefPubMed
3.
Jones RL, Critchley HO (2000) Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Hum Reprod 15(Suppl. 3):162–172CrossRefPubMed
4.
Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T (1986) Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol 5:235–241CrossRefPubMed
5.
6.
Seeber B, Ziehr SC, Gschlieβer A, Moser C, Mattle V, Seger C, Griesmacher A, Concin N, Concin H, Wildt L (2012) Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system. Contraception 86:345–349CrossRefPubMed
7.
Barbosa I, Olsson SE, Odlind V, Goncalves T, Coutinho E (1990) Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 42:51–66CrossRefPubMed
8.
Zhu PD, Luo HZ, Xu RH, Cheng J, Wu SC, Chen JH, Wu MZ, Wang XP (1989) The effect of intrauterine devices, the stainless steel ring, the copper T220, and releasing levonorgestrel, on the bleeding profile and the morphological structure of the human endometrium—a comparative study of three IUDs. Contraception 40:425–438CrossRefPubMed
9.
Hickey M, Crewe J, Mahoney LA, Doherty DA, Fraser IS, Salamonsen LA (2006) Mechanisms of irregular bleeding with hormone therapy: the role of matrix metalloproteinases and their tissue inhibitors. J Clin Endocrinol Metab 91:3189–3198CrossRefPubMed
10.
Luukkainen T, Lähteenmäki P, Toivonen J (1990) Levonorgestrel releasing intrauterine device. Ann Med 22:85–90CrossRefPubMed
11.
Robinson GE, Bounds W, Kubba AA, Adams J, Guillebaud J (1989) Functional ovarian cysts associated with the levonorgestrel releasing intrauterine device. Br J Fam Plann 14:131–132
12.
American College of Obstetricians and Gynecologists Committee on Gynecologic Practice (2006) ACOG Committee Opinion. No337: Noncontraceptive uses of the levonorgestrel intrauterine system. Obstet Gynecol 107:1479–1482CrossRef
13.
World Health Organization (WHO) (2010) Medical Eligibility Criteria for Contraceptive Use-4th ed 2009. WHO, Geneva
14.
Centers for Disease Control and Prevention (2010) US Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm Rep 59(RR-4):1–86
15.
Faculty of Sexual and Reproductive Health Care (2009) The Royal College of Obstetricians and Gynecologists. UK Medical Eligibility Criteria for Contraceptive Use. Faculty of Sexual and Reproductive Health Care, London
16.
Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists (2012) Committee Opinion No539: adolescents and Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstet Gynecol 120:983–988CrossRef
17.
Committee on Adolescence, The American Pediatric Academy (2014) Contraception for Adolescents. Pediatrics 134:1244–1256CrossRef
18.
Lyus R, Lohr P, Prager S, Board of the Society of Family Planning (2010) Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women. Contraception 81:367–371CrossRefPubMed
19.
Caddy S, Yudin MH, Hakim J, Money DM, Infectious Disease Committee; Society of Obstetricians and Gynaecologists of Canada (2014) Best practices to minimize risk of infection with intrauterine device insertion. J Obstet Gynaecol Can 36:266–276CrossRefPubMed
20.
Faculty of Sexual and Reproductive Health Care Clinical Guidance. The Royal College of Obstetricians and Gynecologists (2010) Contraceptive Choices for Young People. Faculty of Sexual and Reproductive Health Care, London
21.
22.
Sexual Health and Family Planning Australia (SH&FPA) (2013). Time for a Change: Increasing the Use of Long-Acting Reversible Contraceptive methods in Australia. SH&FPA
23.
World Health Organization (2002) Adolescent friendly health services—an agenda for change. WHO, Geneva
24.
Berenson AB, Tan A, Hirth JM, Wilkinson GS (2013) Complications and continuation of intrauterine device use among commercially insured teenagers. Obstet Gynecol 121:951–958CrossRefPubMedPubMedCentral
25.
Rosenstock JR, Peipert JF, Madden T, Zhao Q, Secura GM (2012) Continuation of reversible contraception in teenagers and young women. Obstet Gynecol 120:1298–1305CrossRefPubMedPubMedCentral
26.
Amies Oelschlager AM, Micks EA, Debiec KE, Nizamic T, Mantrala MD, Prager SW (2014) Long acting reversible contraception in adolescents with cardiovascular conditions. J Pediatr Adolesc Gynecol 27:353–355CrossRefPubMed
27.
Hillman JB, Miller RJ, Inge TH (2011) Menstrual concerns and intrauterine contraception among adolescent bariatric surgery patients. J Womens Health (Larchmt) 20:533–538CrossRef
28.
Godfrey EM, Memmel LM, Neustadt A, Shah M, Nicosia A, Moorthie M, Gilliam M (2010) Intrauterine contraception for adolescents aged 14–18 years: a multicenter randomized pilot study of levonorgestrel-releasing intrauterine system compared to the Copper T380A. Contraception 81:123–127CrossRefPubMed
29.
Aoun J, Dines VA, Stovall DW, Mete M, Nelson CB, Gomez-Lobo V (2014) Effects of age, parity and device type on complications and discontinuation of intrauterine devices. Obstet Gynecol 123:585–592CrossRefPubMed
30.
Behringer T, Reevers MF, Rossiter B, Chen BA, Schwarz EB (2011) Duration of use of a levonorgestrel IUS amongst nulliparous and adolescent women. Contraception 84:e5–e10CrossRefPubMedPubMedCentral
31.
Teal SB, Sheeder J (2012) IUD use in adolescent mothers: retention, failure and reasons for discontinuation. Contraception 85:270–274CrossRefPubMed
32.
Howard DL, Wayman R, Strickland JL (2013) Satisfaction with and intention to continue Depo-Provera versus the Mirena IUD among post-partum adolescents through 12 months of follow-up. J Pediatr Adolesc Gynecol 26:358–365CrossRefPubMed
33.
Paterson H, Ashton J, Harrison-Woolrych M (2009) A nationwide cohort study of the use of the levonorgestrel intrauterine device in New Zealand adolescents. Contraception 79:433–438CrossRefPubMed
34.
Chi C, Pollard D, Tuddenham EG, Kadir RA (2010) Menorrhagia in adolescents with inherited bleeding disorders. J Pediatr Adolesc Gynecol 23:215–222CrossRefPubMed
35.
Silva CD, Geraldes F, Silva IS (2013) Levonorgestrel intrauterine system as a treatment option for severe menorrhagia in adolescent with type III von Willebrand disease. BMJ Case Rep. doi:10.​1136/​bcr-2013-008833
36.
Yoost J, LaJoie AS, Hertweck P, Loveless M (2013) Use of the levonorgestrel intrauterine system in adolescents with endometriosis. J Pediatr Adolesc Gynecol 26:120–124CrossRefPubMed
37.
Al-Jefout M, Palmer J, Fraser IS (2007) Simultaneous use of a levonorgestrel intrauterine system and an etonogestrel subdermal implant for debilitating endometriosis. Aust N Z J Obstet Gynaecol 47:247–249CrossRefPubMed
38.
Williamson M, Bulmer P (2010) Using the Mirena intrauterine system to treat severe primary dysmenorrhoea in an adolescent. J Obstet Gynaecol 30:206–207CrossRefPubMed
39.
Aslam N, Blunt S, Latthe P (2010) Effectiveness and tolerability of levonorgestrel intrauterine system in adolescents. J Obstet Gynaecol 30:489–491CrossRefPubMed
40.
Pillai M, O’Brien K, Hill E (2010) The levonorgestrel intrauterine system (Mirena) for the treatment of menstrual problems in adolescents with medical disorders, or physical or learning diabilities. BJOG 117:216–221CrossRefPubMed
41.
Savasi I, Jayasinghe K, Moore P, Jayasinghe Y, Grover SR (2014) Complication rates associated with levonorgestrel intrauterine system use in adolescents with developmental disabilities. J Pediatr Adolesc Gynecol 27:25–28CrossRefPubMed
42.
Hillard PJ (2012) Menstrual suppression with the levonorgestrel intrauterine system in girls with developmental delay. J Pediatr Adolec Gynecol 25:308–313CrossRef
43.
Kirkham YA, Allen L, Kives S, Caccia N, Spitzer RF, Omstein MP (2013) Trends in menstrual concerns and suppression in adolescents with developmental disabilities. J Adolesc Health 53:407–412CrossRefPubMed
44.
Brown AJ, Westin SN, Broaddus RR, Schmeler K (2012) Progestin intrauterine device in an adolescent with grade 2 endometrial cancer. Obstet Gynecol 119(2 Pt 2):423–426CrossRefPubMedPubMedCentral
45.
Peipert JF, Madden T, Allsworth JE, Secura GM (2012) Preventing unintended preg-nancies by providing no-cost contraception. Obstet Gynecol 120:1291–1297CrossRefPubMedPubMedCentral
46.
Mestad R, Secura G, Allsworth JE, Madden T, Zhao Q, Peipert JF (2011) Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception 84:493–498CrossRefPubMedPubMedCentral
47.
Friedman JO (2015) Factors associated with contraceptive satisfaction in adolescent women using the IUD. J Pediatr Adolesc Gynecol 28:38–42CrossRefPubMed
48.
Williams CE, Creighton SM (2012) Menstrual disorders in adolescents: review of current practice. Horm Res Paediatr 78:135–143CrossRefPubMed
49.
Arruda MS, Petta CA, Abrao MS, Benetti-Pinto CL (2003) Time elapsed from onset of symptoms to diagnosis of endometriosis in a cohort study of Brazilian women. Hum Reprod 18:4–9CrossRef
50.
American College of Obstetricians and Gynecologists (2005) ACOG Committee Opinion. Number 310, April 2005. Endometriosis in adolescents. Obstet Gynecol 105:921CrossRef
51.
Laufer MR, Goitein L, Bush M, Cramer DW, Emans SJ (1997) Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol 10:199CrossRefPubMed
52.
Tharinger D, Horton CB, Millea S (1990) Sexual abuse and exploitation of children and adults with mental retardation and other handicaps. Child Abuse Negl 14:301CrossRefPubMed
53.
Cromer BA, Scholes D, Berenson A, Cundy T, Clark MK, Kaunitz AM (2006) Depot medroxyprogesterone acetate and bone mineral density in adolescents—the Black Box Warning: a Position Paper of the Society for Adolescent Medicine. J Adolesc Health 39:296–301CrossRefPubMed
54.
Isley MM, Kaunitz AM (2011) Update on hormonal contraception and bone density. Rev Endocr Metab Disord 12:93CrossRefPubMed
55.
American College of Obstetricians and Gynecologists Committee on Adolescent Health Care (2009) ACOG Committee Opinion no. 448: Menstrual manipulation for adolescents with disabilities. Obstet Gynecol 114:1428CrossRef
56.
Atkinson E, Bennett MJ, Dudley J, Grover S, Matthews K, Moore P, Quinlivan J, Walters T, Australian Society of Paediatric and Adolescent Gynaecology Working Party (2003) Consensus statement: Menstrual and contraceptive management in women with an intellectual disability. Aust N Z J Obstet Gynaecol 43:109CrossRefPubMed
57.
Gadelha Da Costa A, Filho FM, Ferreira AC, Spara P, Mauad FM (2004) Uterine volume in adolescents. Ultrasound Med Biol 30:7–10CrossRefPubMed
58.
Holm K, Laursen EM, Brocks V, Müller J (1995) Pubertal maturation of internal genitalia: an ultrasound evaluation of 166 healthy girls. Ultrasound Obstet Gynecol 6:175–181CrossRefPubMed
59.
Kamal I, Hefnawi F, Ghonheim M, Talant M, Abdalla M (1971) Dimensional and architectural disproportion between the intrauterine device and the uterine cavity: a cause of bleeding. Fert Steril 22:514–521CrossRef
60.
Bayer LL, Jensen JT, Li H, Nichols MD, Bednarek PH (2012) Adolescent experience with intrauterine device insertion and use: a retrospective cohort study. Contraception 86:443–451CrossRefPubMed
61.
Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O (1992) Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 339:785–788CrossRefPubMed
62.
Walsh T, Grimes D, Frezieres R, Nelson A, Bernstein L, Coulson A, Bernstein G (1998) Randomized controlled trial of prophylactic antibiotics before insertion of intrauterine devices. IUD Study Group. Lancet 351:1005–1008CrossRefPubMed
63.
ACOG Practice Bulletin No. 121 (2011) Long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol 118:184–196CrossRef
64.
Toivonen J, Luukkainen T, Allonen H (1991) Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years’ comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol 77:261–264CrossRefPubMed
65.
Blanc AK, Tsui AO, Croft TN, Trevitt JL (2009) Patterns and trends in adolescents’ contraceptive use and discontinuation in developing countries and comparisons with adult women. International perspectives on sexual and reproductive health. Int Perspect Sex Reprod Health, p 63–71
Metadata
Title
Usage of the levonorgestrel-releasing intrauterine system (LNG-IUS) in adolescence: what is the evidence so far?
Authors
Magdalini Patseadou
Lina Michala
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 3/2017
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-016-4261-0

Other articles of this Issue 3/2017

Archives of Gynecology and Obstetrics 3/2017 Go to the issue

General Gynecology

Two novel classification systems for uterine fibroids and subsequent uterine reconstruction after myomectomy

General Gynecology

Safety and perioperative morbidity of laparoscopic sacropexy: a systematic analysis and a comparison with laparoscopic hysterectomy

Maternal-Fetal Medicine

Pregnancy outcomes in HIV-positive women: a retrospective cohort study

Gynecologic Endocrinology and Reproductive Medicine

Prediction of fetal loss by first-trimester crown–rump length in IVF pregnancies

Gynecologic Endocrinology and Reproductive Medicine

Retrospective cohort study: AMH is the best ovarian reserve markers in predicting ovarian response but has unfavorable value in predicting clinical pregnancy in GnRH antagonist protocol

Gynecologic Oncology

Increased expression of miR-15b is associated with clinicopathological features and poor prognosis in cervical carcinoma